Stemline Therapeutics Inc. (NASDAQ:STML) shares saw strong trading volume on Wednesday . 362,384 shares were traded during trading, an increase of 136% from the previous session’s volume of 153,507 shares.The stock last traded at $8.20 and had previously closed at $7.69.

A number of research analysts have recently commented on the stock. Jefferies Group reaffirmed a “buy” rating and set a $23.00 price objective on shares of Stemline Therapeutics in a research report on Monday, June 6th. Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research report on Wednesday, July 6th. Wedbush reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday, June 7th. Finally, Roth Capital reaffirmed a “buy” rating and set a $32.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Stemline Therapeutics presently has an average rating of “Buy” and an average target price of $19.31.

The stock has a 50-day moving average of $7.27 and a 200-day moving average of $6.13. The firm’s market capitalization is $142.60 million.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. On average, equities research analysts expect that Stemline Therapeutics Inc. will post ($2.11) EPS for the current fiscal year.

A hedge fund recently raised its stake in Stemline Therapeutics stock. Royce & Associates LLC raised its position in shares of Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned 0.91% of Stemline Therapeutics worth $1,004,000 at the end of the most recent reporting period.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.